Home
Search
Search Results
Previously Searched
3122 results found
Expand All
Apply All
3122 results found

The frightening campaign to keep us unvaccinated
Good Day BIO Newsletter  •  December 21, 2020
Congratulations to BIO member Moderna on the emergency use authorization of your COVID-19 vaccine, the second vaccine to be authorized for use in the United States! These vaccines are safe and effective—but some Americans remain hesitant to get them. We discuss why and how we can tackle it, as well as take a look at what’s needed to grow the bioeconomy moving forward. (920 words, 4 minutes, 36 seconds)
Read More

The payroll R&D credit, five years on
Good Day BIO Newsletter  •  December 18, 2020
Yesterday, an FDA independent advisory panel voted to endorse Moderna’s COVID-19 vaccine, clearing the way for emergency use authorization as soon as today. Meanwhile, we’re taking a look at the payroll R&D tax credit, Washington State’s plans for a low-carbon fuel standard, and whether the federal government will shut down tonight. (767 words, 3 minutes, 50 seconds)
Read More

Survey on Payroll R&D Credit
BIO will soon be launching a survey on the Payroll R&D Credit. This Credit, which was introduced in the PATH Act in 2015, allowed pre-revenue innovators to take a portion of their R&D credit against their payroll tax obligation. The survey will help us assess the impact and usage of the Credit and will support our advocacy in the new Congress. To sign up to receive the survey when it is launched, please fill out the below form.
Read More

Behind CMS' new data on health care spending
Good Day BIO Newsletter  •  December 17, 2020
The FDA Vaccines and Related Biological Products Advisory Committee meets today to discuss emergency use authorization of the Moderna COVID-19 vaccine. In other news, we look at new data on health care spending and the future of gene editing. (916 words, 4 minutes, 34 seconds)
Read More

How Committees Work
Employees of member companies may be involved in committees as much or as little as they want to be. Committee members participate in committee calls to speak up about issues that are important to them, or simply network with peers. Here is a framework in which BIO can help support your objectives:
Read More

“This is the time for us to talk about the science”
Good Day BIO Newsletter  •  December 16, 2020
COVID-19 vaccines are here—but how do we ensure people will get them when it’s their turn? BIO’s Dr. Michelle McMurry-Heath discussed this on CNN. Meanwhile, 2021 is shaping up to be a critical year in the war on climate change, so we take a look at the many ways gene editing can contribute. (834 words, 4 minutes, 10 seconds)
Read More

COVID-19 vaccines are here—but future innovation is at risk
Good Day BIO Newsletter  •  December 15, 2020
The emergency use authorization of a COVID-19 vaccine less than one year after the virus was identified is an amazing feat—but attempts to weaken IP protections could undermine this kind of innovation in the future. We explain why, plus look at how one company is successfully marketing its GM apples to consumers. (871 words, 4 minutes, 20 seconds)
Read More

Technology Transfer
Policy

Happy 40th, Bayh-Dole!
Good Day BIO Newsletter  •  December 14, 2020
It’s a happy Monday indeed with Pfizer-BioNTech vaccine doses on their way to every U.S. state and territory. Meanwhile, ICYMI in the midst of all the vaccine excitement, Bayh-Dole turned 40 and Congress passed the defense spending bill with a boost for the bioeconomy. (1,000 words, 5 minutes)
Read More

FDA panel recommends authorization of Pfizer-BioNTech vaccine
Good Day BIO Newsletter  •  December 11, 2020
It’s Friday. Congress is working to avoid a government shutdown today. Meanwhile, we have a recap of yesterday’s FDA advisory committee meeting on the Pfizer-BioNTech vaccine as well as details of a new group working to advance Black professionals in the agriculture industry. (727 words, 3 minutes, 38 seconds)
Read More